The Patent Finder

Sotio Biotech Inc.

Also on record
Records under this name other than the patents Sotio Biotech Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 2 patents it holds.

Back to Sotio Biotech Inc.

Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
PatentTitleStatus Expires Confidence
17/257,469Chimeric Receptors in Combination with Trans Metabolism Molecules Enhancing Glucose Import and Therapeutic Uses Thereof
Abandoned
Abandoned Jan 15, 2025
AbandonedAbandoned Jan 15, 2025
17/274,021Chimeric Receptor Polypeptides in Combination with Trans Metabolism Molecules Modulating Intracellular Lactate Concentrations and Therapeutic Uses Thereof
Abandoned
Abandoned Sep 4, 2024
AbandonedAbandoned Sep 4, 2024
17/291,963ANTI-GPC3 Chimeric Antigen Receptors (CARs) in Combination with Trans Co-Stimulatory Molecules and Therapeutic Uses Thereof
Abandoned
Abandoned Dec 19, 2024
AbandonedAbandoned Dec 19, 2024
17/788,226Tumor-Specific Claudin 18.2 Antibodies
Pending
Term is not computable until grant, so no date is shown and no estimate is implied.
PendingTerm is not computable until grant, so no date is shown and no estimate is implied.
18/573,387Interleukin 15 Variants
Pending
Term is not computable until grant, so no date is shown and no estimate is implied.
PendingTerm is not computable until grant, so no date is shown and no estimate is implied.
18/573,397INTERLEUKIN-15 Based Immunocytokines
Pending
Term is not computable until grant, so no date is shown and no estimate is implied.
PendingTerm is not computable until grant, so no date is shown and no estimate is implied.
18/695,383Chimeric Receptor Polypeptides in Combination with Trans Metabolism Molecules That Re-Direct Glucose Metabolites Out of the Glycolysis Pathway and Therapeutic Uses Thereof
Pending
Term is not computable until grant, so no date is shown and no estimate is implied.
PendingTerm is not computable until grant, so no date is shown and no estimate is implied.
18/709,546Treatment of Myxoid/Round Cell Liposarcoma Patients
Pending
Term is not computable until grant, so no date is shown and no estimate is implied.
PendingTerm is not computable until grant, so no date is shown and no estimate is implied.
18/784,028Chimeric Antigen Receptor Polypeptides in Combination with Trans Metabolism Molecules Modulating Krebs Cycle and Therapeutic Uses Thereof
Pending
Term is not computable until grant, so no date is shown and no estimate is implied.
PendingTerm is not computable until grant, so no date is shown and no estimate is implied.
19/104,547Genetically Engineered Immune Cells with Chimeric Receptor Polypeptides in Combination with Multiple Trans Metabolism Molecules and Therapeutic Uses Thereof
Pending
Term is not computable until grant, so no date is shown and no estimate is implied.
PendingTerm is not computable until grant, so no date is shown and no estimate is implied.
10 of 11 records shown.
Pro members see all 11.
Pro members: see all 11 records
The Patent Finder CompaniesExpirationsCalculatorWatchlistPricing MethodologyCorrectionsLegalPrivacysupport@thepatentfinder.com Updated Nov 19, 2026 · includes USPTO assignment data published Nov 18, 2026, status data published Nov 19, 2026 and grant & fee data published Nov 17, 2026 (weekly) Part of 137 Finder · © 2026 137 Finder LLC · Sources cited